艾塞那肽周制剂联合达格列净对比单药治疗2型糖尿病52周结果
DURATION-8随机双盲研究显示,二甲双胍控制不佳的2型糖尿病患者中,艾塞那肽周制剂联合达格列净治疗52周时HbA1c降幅大于艾塞那肽或达格列净单药,体重和收缩压降幅大于艾塞那肽单药,安全性与单药类似,无意外发现。
要点
- 联合治疗52周HbA1c降幅大于艾塞那肽单药和达格列净单药。
- 联合治疗体重和收缩压降幅大于艾塞那肽单药,与达格列净单药相似。
- 联合治疗耐受性良好,无意外安全性发现,无重大低血糖发生。
核心结论
- 在二甲双胍控制不佳的2型糖尿病患者中,艾塞那肽周制剂联合达格列净治疗52周持续改善血糖、体重和收缩压,无意外安全性发现。
研究设计与样本
- 3期、多中心、双盲随机对照试验,纳入成人2型糖尿病患者(HbA1c 8.0-12.0%且二甲双胍≥1500 mg/日),随机分配至艾塞那肽周制剂联合达格列净、艾塞那肽周制剂联合口服安慰剂或达格列净联合注射安慰剂,共695例随机化,81.2%完成研究。
主要发现
- 52周时,联合治疗组HbA1c最小二乘均值变化为-1.75%,艾塞那肽单药组为-1.38%(P=0.006),达格列净单药组为-1.23%(P<0.001)。
- 52周时,联合治疗组平均HbA1c为6.9%,艾塞那肽单药组为7.2%,达格列净单药组为7.4%。
- 52周时,联合治疗组体重变化为-3.31 kg,收缩压变化为-4.5 mmHg;艾塞那肽单药组体重变化为-1.51 kg,收缩压变化为-0.7 mmHg(均P<0.001)。
- 52周时,联合治疗组体重变化为-3.31 kg,收缩压变化为-4.5 mmHg;达格列净单药组体重变化为-2.28 kg(P=0.057),收缩压变化为-2.7 mmHg(P=0.100)。
- 联合治疗组耐受性良好,无意外安全性发现;艾塞那肽周制剂治疗患者胃肠道和注射部位相关不良事件更多;无重大低血糖发生。
临床怎么用
- 对于二甲双胍控制不佳的2型糖尿病患者,可考虑艾塞那肽周制剂联合达格列净治疗以持续改善血糖、体重和收缩压。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Among patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin combination produced greater reductions in glycemia, weight, and systolic blood pressure (SBP) at 28 weeks than exenatide QW or dapagliflozin alone (DURATION-8). Here, we investigated the safety and maintenance of efficacy at 52 weeks, after a 24-week extension. RESEARCH DESIGN AND METHODS: This phase 3, multicenter, double-blind study randomized adults with type 2 diabetes (with glycated hemoglobin [HbA1c] 8.0-12.0% [64-108 mmol/mol] and on metformin ≥1,500 mg/day) to exenatide QW (2-mg subcutaneous injection) plus once-daily dapagliflozin (10-mg oral tablet), exenatide QW plus oral placebo, or dapagliflozin plus injected placebo. Extension-period P values were nominal. RESULTS: Of 1,375 patients screened, 695 were randomized (mean baseline HbA1c 9.3% [78 mmol/mol]); 81.2% completed the study, and 75.3% completed treatment. At 52 weeks, HbA1c reductions were greater with exenatide QW plus dapagliflozin (least squares mean change -1.75% [-19.1 mmol/mol]) versus exenatide QW (-1.38% [-15.1 mmol/mol]; P = 0.006) or dapagliflozin (-1.23% [-13.4 mmol/mol]; P < 0.001); mean HbA1c values were 6.9% (52 mmol/mol), 7.2% (55 mmol/mol), and 7.4% (57 mmol/mol), respectively. Weight and SBP reductions were greater with exenatide QW plus dapagliflozin (-3.31 kg and -4.5 mmHg) versus exenatide QW (-1.51 kg and -0.7 mmHg; both P < 0.001) but similar to those with dapagliflozin (-2.28 kg and -2.7 mmHg; P = 0.057 and P = 0.100, respectively). The exenatide QW plus dapagliflozin regimen was well tolerated with no unexpected safety findings; more patients treated with exenatide QW experienced gastrointestinal and injection site-related adverse events. No major hypoglycemia occurred. CONCLUSIONS: Among patients with type 2 diabetes uncontrolled with metformin, exenatide QW plus dapagliflozin provided sustained improvements in glycemia, weight, and SBP over 52 weeks, with no unexpected safety findings.
引用
- Jabbour SA, Frías JP, Hardy E, et al. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. Diabetes Care. 2018. PMID: 30082326. doi:10.2337/dc18-0680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。